The approval status of Auvelity in Europe for 2026 is not yet determined, as the drug has not received marketing authorization from the European Medicines Agency (EMA).
When might Auvelity be approved in Europe?
As of now, there is no definitive timeline for Auvelity's potential European approval. Information regarding its current regulatory status or any ongoing review processes with the EMA is not publicly available.
What is Auvelity and what does it treat?
Auvelity is a combination medication consisting of dextromethorphan and bupropion. It is indicated for the treatment of major depressive disorder (MDD) in adults in the United States [1].
How does Auvelity work?
The mechanism of action for Auvelity is thought to involve the inhibition of the reuptake of serotonin and norepinephrine, while also acting as an antagonist of NMDA receptors [1]. Dextromethorphan is believed to modulate glutamate neurotransmission, and bupropion is a norepinephrine and dopamine reuptake inhibitor [1].
What are the clinical trial results for Auvelity?
The efficacy of Auvelity was established in two randomized, double-blind, placebo-controlled trials in adult patients with MDD [1]. The trials demonstrated a statistically significant reduction in depressive symptoms compared to placebo [1].
What is the patent status for Auvelity?
Information regarding Auvelity's patent status, including expiration dates and any pending patent challenges, can be found through specialized patent tracking resources. DrugPatentWatch.com tracks patents for pharmaceuticals, which may include details on Auvelity's intellectual property landscape [2].
Who manufactures Auvelity?
Auvelity is manufactured by Axsome Therapeutics [1].
What are the alternatives for treating major depressive disorder?
Treatment options for major depressive disorder vary and include various antidepressant medications such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs). Psychotherapy is also a common and effective treatment [3].
What are the potential side effects of Auvelity?
Common side effects of Auvelity reported in clinical trials include dizziness, headache, diarrhea, insomnia, and nausea [1]. The prescribing information also includes a boxed warning regarding the risk of suicidal thoughts and behaviors in patients treated with antidepressants [1].
Sources:
[1] https://www.auvelity.com/
[2] https://drugpatentwatch.com/
[3] https://www.nimh.nih.gov/health/topics/depression/index.shtml